Glide Pharma has been awarded a sub-contract from Pfenex, Inc. to develop a solid formulation of recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfenex Expression Technology for delivery with the Glide SDI (solid dose injector). The goal is to address logistical constraints of the currently available vaccine, namely, long-term stability during storage and ease of administration.   The Pfenex project has been funded with Federal funds from the National Institute of Aller...